RA0410

antibody from Oursmab
Targeting: IL7R CD127, IL7RA
Provider product page for RA0410
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0410 - Provider product page
Provider
Oursmab
Product name
Lusvertikimab (Biosimilar Reference Antibody) (IL7R)
Antibody type
Monoclonal
Description
Lusvertikimab is a humanized IgG4-kappa monoclonal antibody that specifically targets the interleukin-7 receptor (IL-7R). The IgG4 isotype is selected to minimize effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), focusing the mechanism on receptor blockade. By binding to IL-7R, it inhibits the interaction between the receptor and its cytokine, IL-7, thereby blocking downstream JAK/STAT signaling. This pathway is critical for the development, survival, and homeostasis of T cells and B cells. It is being developed as a potential therapeutic for autoimmune and inflammatory diseases where dysregulated IL-7/IL-7R signaling contributes to pathogenesis, such as rheumatoid arthritis, multiple sclerosis, or inflammatory bowel disease (IBD).
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
IL7R protein structure - RA0410 shown in red.